Edwards Lifesciences announced the company’s Evoque tricuspid valve replacement system is the first transcatheter therapy to receive FDA approval for the treatment of tricuspid regurgitation, or TR. The Evoque system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy, or OMT, for whom tricuspid valve replacement is deemed appropriate by a heart team.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Early notable gainers among liquid option names on January 31st
- Edwards Lifesciences price target raised to $82 from $80 at RBC Capital
- Edwards Lifesciences downgraded to In Line from Outperform at Evercore ISI
- Edwards Lifesciences price target raised to $84 from $78 at Truist
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
